



## ASX Release

### APPENDIX 3Y - CORRECTION

**Melbourne, Australia: 8 April 2019:** Jayex Healthcare Limited (**ASX:JHL**) (**JHL** or **Company**) advises that the attached Appendix 3Y – Change in Director’s Interest Notice replaces that notice for Mr Michael Boyd lodged with the ASX on 2 April 2019.

The previously lodged Appendix 3Y inadvertently included incorrect details with regard to the number of fully paid ordinary shares acquired by Mr Boyd.

A corrected Appendix 3Y for Mr Boyd is attached.

**Ends**

#### Contacts for further information:

##### Investor Enquiries

Chief Executive Officer  
Nick Fernando  
1300 330 611  
[n.fernando@jayex.com](mailto:n.fernando@jayex.com)

Company Secretary  
Melanie Leydin  
+61 3 9692 7222

#### Forward looking statements

This announcement contains forward-looking statements. All statements that address events or developments that we expect or anticipate will or may occur in the future are forward-looking statements. These forward-looking statements are based on the Board or management’s beliefs and expectations based on information currently available to the Board and management. The Company believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements which are inherently uncertain. The Company does not undertake any obligation to publicly update or revised any forward-looking statements whether as a result of new information, future events or otherwise except as required by law or the ASX Listing Rules. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from the Company’s historical experience, or present expectations or projections.

About Jayex Healthcare Limited - [www.jayexhealthcare.com.au](http://www.jayexhealthcare.com.au)

---

Jayex Healthcare is a leading provider of integrated healthcare services delivery platforms in the United Kingdom and Australia, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
  - the *Appointuit* patient engagement solution;
  - the *Pharmacy Delivery 2 U (P2U®)* prescription delivery service; and
  - the *BluePoint®* remote pharmacy prescription processing and dispensing terminal.
-

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	Jayex Healthcare Limited
ABN	15 119 122 477

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Boyd
Date of last notice	27 March 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Michael Boyd has a relevant interest, in accordance with section 608(3)(b) of the Corporations Act 2001 (Cth), in the securities held by Covenant Holdings (WA) Pty Ltd through his position as controlling Shareholder of that company.
Date of change	(a) 27 March 2019 (b) 28 March 2019 (c) 29 March 2019
No. of securities held prior to change	<u>Covenant Holdings (WA) Pty Ltd</u> 78,998,079 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	(a) 28,645 Fully paid ordinary shares (b) 71,487 Fully paid ordinary shares (c) 19,128 Fully paid ordinary shares
Number disposed	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$4,174.10
<b>No. of securities held after change</b>	<u>Covenant Holdings (WA) Pty Ltd</u> 79,117,339 fully paid ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.